#United States #San Diego #Solu Therapeutics #STX-0712 #CMML

Positive Preclinical Findings for STX-0712

Solu Therapeutics, a trailblazer in biotechnology focused on eliminating disease-promoting cells across various medical spheres, recently revealed promising preclinical results concerning their compound STX-0712. This innovative drug, featuring the CCR2-CyTAC™, emerges as a potential treatment for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).

Key Unveiling at ASH Annual Meeting

The results were disclosed during the American Society of Hematology (ASH) Annual Meeting held from December 7-10, 2024, in sunny San Diego, California. The Chief Medical Officer at Solu, Sergio Santillana, expressed enthusiasm about the findings, emphasizing the groundbreaking capabilities of their CyTAC platform in selectively targeting disease-causing cells.

Robust Activity Against CCR2-positive Monocytes

The results presented showcased STX-0712's formidable capability to target CCR2-positive malignant monocytes, particularly in challenging cases like CMML and AML. In preclinical evaluations, several notable insights emerged:

• - CCR2 Expression in CMML: Over 98% of malignant monocytes from CMML patients showed high CCR2 expression, while its presence was minimal in healthy controls. This established CCR2 as a reliable target for treatment.

• - Efficacy in Monocyte Depletion: STX-0712 demonstrated an impressive ability to deplete CD14+CCR2+ monocytes in all tested patient samples, with cancer cell elimination rates varying between 66% to 91%. The compound had a striking average potency of 3nM.

• - Performance in Non-Human Primates: Studies in non-human primates further validated these results, revealing that STX-0712 effectively eliminated over 95% of CCR2-positive monocytes without notable side effects, indicating its well-tolerated nature.

Breakthrough Results in AML

Focusing on AML, the findings revealed that:

• - Strong CCR2 Expression: Malignant monocytes from AML patients exhibited significant CCR2 levels, especially in acute monocytic and acute myelomonocytic leukemia cases.
• - Success in Reducing Malignant Cells: Approximately 80% of AML patient samples responded positively to STX-0712, achieving up to 74% cancer cell depletion, again showcasing an average potency of 3nM.
• - Enhanced Efficacy with Combination Treatments: When combined with existing therapies like venetoclax and azacitidine, STX-0712 improved treatment outcomes in 60% of the tested samples, further underscoring its potential.

Future Endeavors for Solu Therapeutics

The encouraging data discussed at the ASH meeting symbolizes a pivotal achievement for Solu, as highlighted by the company's Co-founder and Chief Technology Officer Brandon Turunen. He articulated the critical importance of targeting the root mechanisms behind CMML and AML, which often lack effective targeted therapies. The selective targeting approach of STX-0712 not only signifies a leap forward in potential treatment avenues but also maintains a notable safety profile.

Solu Therapeutics is set to continue its dedicated efforts in advancing STX-0712 through clinical trials in 2025 while harnessing its innovative CyTAC platform for addressing a broad array of diseases in need of novel treatments.

About Solu Therapeutics

Headquartered in Boston, Solu Therapeutics is at the forefront of developing innovative therapeutics aimed at dismantling disease-promoting cells across cancer and immunology fields. Their proprietary platforms, CyTAC and TicTAC, harness the benefits of small molecules and biotherapeutics to create next-generation treatments. As they forge ahead, Solu remains committed to delivering transformative therapies for patients facing difficult-to-treat illnesses.